

Impact of the COVID-19 Pandemic on HIV Care in a Paediatric and Adolescent ARV Clinic in Johannesburg: A Retrospective Cohort Study

Student: Dr Masello Phasha

Student Number: 358603

Degree: Master of Medicine in Paediatrics and Child
Health

Supervisors:

Dr Gillian Sorour, Paediatric Infectious Diseases,
Rahima Moosa Mother and Child Hospital

Assoc. Prof. Karl-Günter Technau, Empilweni Services
and Research Unit, Rahima Moosa Mother and Child
Hospital

14 October 2024



DECLARATION

I, Masello Phasha hereby declare that this dissertation titled Impact of the COVID-19 Pandemic on HIV Care in a Paediatric and Adolescent ARV Clinic in Johannesburg: A Retrospective Cohort Study, submitted in fulfilment of the requirements for the Master of Medicine degree in Paediatrics and Child Health is my original work.

This dissertation was conducted under the supervision of Dr Gillian Sorour and Prof. Karl-Günter Technau in the Department of Paediatrics and Child Health, Rahima Moosa Mother and Child Hospital.

I have acknowledged all sources of information I have used and have conformed to the University of the Witwatersrand requirements regarding intellectual property and plagiarism.

I declare that this dissertation has not been submitted in whole or in part for any other degree or qualification at any other institution.

Signed:  _____

Date: 14 October 2024

DEDICATION

I dedicate this dissertation to my lovely family, to my beloved late father who always believed in me and encouraged me to reach for the stars. This dissertation is dedicated to your memory.

A special word of gratitude to my mother for her support and unconditional love.

To my very special sister Mabatho and my brother Mfundis who stood by me and were always willing to lend a helping hand, your thoughtfulness is appreciated.

To my husband Green and our dearest daughter Mokgethwa for their constant love, encouragement and for walking this journey with me.

I also dedicate this work to my friends who have demonstrated what it means to be closer than a brother and for their sweet friendship that has kept me going.

Lastly, I wish to give special thanks to my Let's go to glory church family who have supported me and covered me in prayer.

ACKNOWLEDGEMENTS

First and most important I give praise and thanks to God who has kept me and enabled me to complete this dissertation.

I wish to thank my supervisors Dr Sorour and Prof Technau for their invaluable guidance, input and endless support throughout this journey. Thank you for your time, insightful feedback and many hours of reading this manuscript to perfection. It has been a privilege to be supervised by you and I will forever be grateful for the experience.

I acknowledge and thank the Empilweni Services and Research Unit together with the Department of Paediatrics and Child Health at Rahima Moosa Mother and Child Hospital for allowing me to conduct my research and aiding when required.

I would like to acknowledge the staff at Empilweni Services and Research unit for their commitment to patient care and their efforts in capturing data which has been crucial for this dissertation.

Finally, I would like to thank the patients which without this work would have not been possible.

Table of Contents

DECLARATION	II
DEDICATION.....	III
ACKNOWLEDGEMENTS	IV
NOMENCLATURE	VII
TITLE PAGE.....	VIII
ABSTRACT	X
INTRODUCTION	1
RESEARCH METHODS AND DESIGNS	3
STUDY DESIGN	3
DATA COLLECTION.....	3
DATA ANALYSIS	4
ETHICAL CONSIDERATIONS	6
RESULTS	6
DEMOGRAPHICS AT PRESENTATION.....	6
CLINICAL FEATURES	7
OUTCOMES	8
DISCUSSION	9
LIMITATIONS	13
CONCLUSION	13
ACKNOWLEDGEMENTS	14
REFERENCES.....	15
ETHICS CLEARANCE CERTIFICATE	18
RESEARCH PROTOCOL.....	25
SUBMISSION GUIDELINES TO THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE	49

LIST OF FIGURES

Figure 1: Selection Process of The Study Population- From Initial Screening to Final Cohort.....	18
Figure 2: Total number of patients who presented to the HIV clinic during the two study periods; 2018- 2019 (pre-COVID era) and 2020- 2021 (COVID era)	19
Figure 3: Age of the patients at presentation to the HIV clinic in age groups during the two time periods; 2018-2019 (pre-COVID era) and 2020- 2021 (COVID era).....	20

LIST OF TABLES

Table 1: First visit demographics and clinical characteristics of patients at presentation	21
Table 2: Treatment Outcomes of patients enrolled in care during the two study periods; 2018-2019 (pre-COVID) and 2020- 2021 (COVID) at one year post enrolment into care.....	22
Table 3: Neonatal diagnosis demographics and treatment outcomes	23

NOMENCLATURE

AIDS	- Acquired Immunodeficiency Syndrome
ART	- Antiretroviral Therapy
ARV	- Antiretroviral
BMI	- Body Mass Index
COVID- 19	- Coronavirus disease 2019
ELISA	- Enzyme-linked immunosorbent assay
ESRU	- Empilweni Services and Research unit
HIV	- Human Immunodeficiency Virus
JHB	- Johannesburg
NWFA	- Normal Weight For Age
PCR	- Polymerase Chain Reaction
PLWHIV	- People Living with HIV
PMTCT	- Prevention of Mother to Child Transmission
RMMCH	- Rahima Moosa Mother and Child Hospital
SA	- South Africa
SARS-CoV-2	- Severe Acute Respiratory Syndrome Coronavirus 2
TB	- Tuberculosis
UWFA	- Underweight For Age
VL	- Viral load
VTP	- Vertical Transmission Prevention
WFH	- Weight For Height
WHO	- World Health Organisation

TITLE PAGE

Date: 14 October 2024

Title of article: Impact of the COVID-19 Pandemic on HIV Care in a Paediatric and Adolescent ARV Clinic in Johannesburg: A Retrospective Cohort Study

Corresponding author: Masello Phasha

Dear Editor-in-Chief

I wish to submit my original research paper entitled “Impact of the COVID-19 Pandemic on HIV Care in a Paediatric and Adolescent ARV Clinic in Johannesburg: A Retrospective Cohort Study” for consideration for publication by the Southern African Journal of HIV Medicine. I declare that this work has not been submitted for publication elsewhere.

Dr Gillian Sorour and Prof. Karl-Günter Technau have co-authored the manuscript. In this paper, we describe the impact of the COVID-19 pandemic on paediatric and adolescent HIV care at a Johannesburg HIV clinic.

The COVID-19 pandemic has had a profound impact on various sectors globally, its co-existence with the HIV/AIDS epidemic in South Africa challenged the healthcare sector and impacted healthcare service delivery, which includes HIV care services for children and adolescents.

In this paper, we highlight the impact of the COVID-19 pandemic on HIV care at a Johannesburg HIV clinic and describe the components of care which were affected by the pandemic. We report on how the pandemic negatively affected the enrolment of children and adolescents into HIV care and the vertical transmission prevention program. We also highlight the ongoing difficulties with early treatment care and monitoring in children and adolescents.

I believe it will be of interest to readers in the field of infectious diseases and HIV medicine. I look forward to the opportunity to share my research paper with the audience of the Southern African Journal of HIV Medicine.

Regards,
Dr Masello Phasha, MB Bch, DCH (SA)

Title:

Impact of the COVID-19 Pandemic on HIV Care in a Paediatric and Adolescent ARV Clinic in Johannesburg: A Retrospective Cohort Study

Authors:

Masello Phasha, Gillian Sorour, Karl-Günter Technau

Affiliations:

Department of Paediatrics and Child Health, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand.

Department of Paediatrics, Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa.

Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa.

Keywords: Paediatric, Adolescent, HIV care, ARV clinic, COVID-19, pandemic

Corresponding author:

Masello Phasha, masellophasha@gmail.com

ABSTRACT

Background:

The co-existence of the HIV/AIDS epidemic and the COVID-19 pandemic in South Africa challenged the healthcare sector and negatively impacted healthcare service delivery, including through impeding access to primary healthcare services which include HIV care services for children and adolescents.

Objectives:

We describe the impact of the COVID-19 pandemic on paediatric and adolescent HIV care at an HIV clinic in Johannesburg, South Africa.

Method:

A retrospective cohort study was conducted on data from the Empilweni Services and Research Unit (ESRU) database, and a secondary data analysis was performed by comparing data of children and adolescents aged 0-18 years who had their first visit during the two study periods; March 2018- February 2019 (pre-COVID era) and March 2020- February 2021 (COVID era).

Results:

During the COVID era, a total of 113 children and adolescents were enrolled into HIV care, reflecting a 27% decline from the pre-COVID era where 154 enrolments occurred. Additionally, there was a significant decrease in the number of neonates referred via the Vertical Transmission Prevention (VTP) program, previously known as the 'Prevention of Mother-to-Child Transmission (PMTCT) program' (45 pre-COVID compared to 20 in the COVID era). However, no significant difference was observed in adherence patterns and treatment outcomes between the two study periods.

Conclusion:

The COVID-19 pandemic negatively impacted the enrolment of children and adolescents into HIV care and affected the VTP program negatively. This is evidenced by a decline in the total number of children and adolescents enrolled in

care during this period. However, there was no significant impact on the outcomes of HIV care.

What this study adds:

The findings emphasise the need to actively strengthen HIV care services, especially HIV testing and treatment monitoring in children, adolescents, and pregnant women. Moreover, it is essential to ensure that these services are not interrupted, particularly during times of crisis, such as the COVID-19 pandemic.

INTRODUCTION

South Africa is heavily affected by the HIV/AIDS (Human Immunodeficiency Virus/ Acquired Immunodeficiency Syndrome) epidemic, which remains a significant public health concern despite advancements in HIV prevention, testing and treatment.¹⁻³ Globally, an estimated 38.4 million people were living with HIV at the end of 2021, with 7.5 million residing in South Africa, including 270 000 children between the ages of 0-14 years.¹

To curb the HIV epidemic, the Joint United Nations Programme on HIV/AIDS (UNAIDS) introduced a set of targets in the year 2020 termed the 95-95-95 targets.⁴ The objective of these targets is to aid in the attainment of the 2030 HIV sustainable development goal 3.3, which is to end the HIV/AIDS epidemic as a public health threat by 2030 by enabling early diagnosis, timely treatment and effective management of the disease.⁵ Specifically, the goal is to ensure that 95% of individuals living with HIV are aware of their HIV status, 95% of all individuals living with HIV infection are receiving antiretroviral therapy, and that 95% of all patients receiving antiretroviral therapy have attained viral suppression by 2025.⁴ Pertaining to children, these targets aim to ensure that 95% of women of childbearing age have their HIV and sexual and reproductive health service needs met, that 95% of breastfeeding mothers living with HIV have attained viral suppression, and that 95% of children born to mothers living with HIV are tested for HIV by 2030.⁴

By the end of 2021, 94% of people living with HIV in South Africa knew their HIV status, of whom 79% were on treatment, and 91% of those on treatment had achieved viral suppression.¹ These figures serve as positive indicators for monitoring progress towards the commitment to achieving the UNAIDS 2025 HIV services targets and the United Nations 2030 HIV sustainable development goal.⁵ However, evidence suggests that further efforts are needed as only 67% of people living with HIV in South Africa had suppressed viral loads by the end of 2021.¹ Sadly, the figures for children are significantly worse with only 83% of children living with HIV in South Africa being diagnosed, 48% starting ART and only 33% having achieved viral

31 suppression by the end of 2021.⁶ This highlights the vulnerability of children in this
32 context.

33
34 Globally, there are 2.73 million children between the ages of 0 and 19 years living
35 with HIV, approximately 850 children become infected with HIV daily and 301
36 children die from AIDS-related illnesses each day.¹ In South Africa, HIV infection
37 remains amongst the five leading causes of under-five mortality, alongside
38 malnutrition, diarrhoeal diseases, lower respiratory tract infections, and low birth
39 weight.² However, only 48% of children living with HIV in South Africa were reported
40 to be on antiretroviral therapy (ART) and tragically, 2800 children died from HIV-
41 related infections in the year 2021.⁷

42
43 The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-
44 CoV-2) in Wuhan, China and its rapid global spread, high morbidity and mortality led
45 the World Health Organisation (WHO) to declare it a pandemic in March 2020,
46 naming it the COVID-19 pandemic.

47 On 27 March 2020, the president in consultation with a panel of experts implemented
48 a national lockdown in South Africa. This measure aimed to curb infection, protect
49 those most vulnerable to severe disease and prepare and safeguard healthcare
50 services as the pandemic was anticipated to overwhelm the healthcare system, as
51 observed in other low and middle-income countries (LMIC) thereby causing
52 disruptions in health care delivery.⁸

53
54 HIV testing is a crucial aspect of HIV care as it identifies people living with HIV and is
55 the first step towards enrolment into HIV care. If testing is disrupted due to any
56 cause, such as the reassignment of dedicated HIV community health workers to
57 other tasks during the COVID-19 pandemic, it can contribute to the decline in the
58 number of children and adolescents being enrolled into HIV care.⁹

59
60 The implementation of the national lockdown coupled with people's fear of
61 contracting SARS-Cov-2 infection led to an unfortunate disruption of child health and
62 antenatal care services, particularly during the initial months of the lockdown. As a
63 result, there was a decline in the number of children and pregnant women accessing
64 essential primary healthcare services.¹⁰ HIV care services were not spared as a

study conducted in KwaZulu-Natal (KZN) reported an almost 50% decline in HIV testing and initiation of antiretroviral therapy (ART) at the onset of the pandemic in South Africa.¹¹

This study aimed to assess the impact of the COVID-19 pandemic on HIV care at the Paediatric and Adolescent HIV Clinic at Rahima Moosa Mother and Child Hospital (RMMCH) by comparing components of HIV care data for new patients enrolled in care before and during the pandemic.

RESEARCH METHODS AND DESIGNS

Study design

This study is a retrospective cohort study conducted at the Rahima Moosa Mother and Child Hospital's paediatric and adolescent HIV clinic also known as Empilweni Services and Research Unit (ESRU) located in the western part of Johannesburg, South Africa. This clinic is a large paediatric and adolescent HIV clinic in South Africa and serves the greater western Johannesburg area, which has the second-highest number of children living with HIV in South Africa.³

The study population included patients aged 0-18 years who attended the HIV clinic as new referrals during two periods; 01 March 2018 – 28 February 2019 (pre-COVID era) and 01 March 2020 – 28 February 2021 (COVID era). Patients who were not HIV-infected and those whose parents refused consent were excluded from the study.

Data Collection

We conducted a secondary analysis on data from the ESRU database, which is hosted on the University of the Witwatersrand REDCAP platform and maintained in the clinic.¹² We obtained approval from the electronic gatekeeper to access de-identified data which we extracted and used exclusively to generate the results for this study.

95

96 **Data Analysis**

97 Descriptive statistics were used to describe the data: Frequencies and percentages
98 for categorical data and medians, and interquartile ranges for continuous data.

99 When examining the referral sources of the patients, we considered a patient to have
100 been referred from the Vertical Transmission Prevention program if they were born in
101 the hospital and had a positive HIV polymerase chain reaction (PCR) test post-
102 delivery (also known as Birth PCR) or two post-delivery indeterminate PCRs followed
103 by a detectable viral load. An inpatient was defined as a patient who tested positive
104 for HIV during their hospital admission and was not receiving treatment at the time.
105 On the other hand, an outpatient was classified as a patient referred by another
106 clinic, not requiring hospitalisation and not receiving ART at their first visit to ESRU.
107 A transfer-in was recorded as any patient who had already been diagnosed with HIV
108 infection and was receiving ART at their first visit to ESRU.

109

110 An early presentation, from diagnosis to the first visit was defined as any patient who
111 had been diagnosed with HIV infection less than eight days before their first ESRU
112 visit while a late presentation was any patient who had been diagnosed with HIV
113 infection eight or more days before their first visit.

114

115 Neonates were excluded from the anthropometry analysis due to variations in
116 birthweights and different methods used to assess adequate weight gain at different
117 time points post-delivery. Ideally, weight for height (WFH) should be used to
118 determine children's nutritional status under five years of age while body mass index
119 (BMI) is preferred in children older than five years of age. Unfortunately, due to
120 incomplete height data, this could not be assessed, and weights only were used to
121 determine whether participants were underweight for age (UWFA) or had a normal
122 weight for age (NWFA). Patients were categorised as UWFA if their weight for age
123 fell below the -2 standard deviations (SD) and as NWFA if their weight for age was
124 between the -2SD and +2SD.

125 The World Health Organisation (WHO) clinical stages were employed to assess the
126 patient's clinical condition at presentation and thereafter patients were classified as
127 mild or advanced disease. Mild disease comprised of patients who were classified as

128 WHO stage 1 and 2, while advanced disease where patients who were classified as
129 WHO stage 3 and 4.

130 Immunological staging was determined based on the WHO case definitions, which
131 utilise CD4 count in percentages for children under 5 years of age and absolute
132 counts for children aged five years and older. Normal CD4 counts were defined as
133 an absolute CD4 cell count of 1000 cells per cubic millimetre and more or a CD4
134 percentage of 25% or more in children less than 5 years, while for children and
135 adolescents 5 years and older an absolute CD4 cell count of 500 cells per cubic
136 millimetre, and more was considered normal. We categorised immunosuppression
137 into two levels: mild and advanced. For children under 1 year of age, mild
138 immunosuppression was defined as a CD4 percentage of 25% or higher while
139 advanced immunosuppression was classified as a CD4 percentage below 25%. In
140 children between 1 and 5 years of age, mild immunosuppression was characterised
141 as a CD4 percentage of 20% or higher, while advanced immunosuppression was
142 indicated by a CD4 percentage below 20%. For all patients aged 5 years and older,
143 mild immunosuppression was defined as an absolute CD4 count of 350 or more cells
144 per cubic millimetre (mm³) and advanced immunosuppression when the absolute
145 CD4 count fell below 350 cells/mm³.

146 Loss to follow-up was defined as the patient's failure to attend their scheduled
147 medication refill or clinical visit beyond 90 days from their last appointment. A patient
148 was classified as transferred out if they were successfully and formally referred to
149 another healthcare facility for continued care. Lastly, a patient was considered virally
150 suppressed if their viral load was lower than 50 copies per millilitre (ml) as per South
151 African guidelines during the study periods. We also assessed viral suppression at
152 the level of 1000 copies per ml.

153

154 Statistical analysis was performed using Statistical Analysis System (SAS – SAS
155 institute Inc, Cary, NC, USA) and a p-value of less than 0.05 was used to indicate a
156 statistically significant finding. When comparing the characteristics above between
157 the groups, we used t-test for continuous data and chi-square for categorical data.
158 Survival analysis using the log-rank test was done to compare death and loss to
159 follow-up between the two periods.

Ethical considerations

The permissions to conduct the study were obtained from the Chief Executive Officer's (CEO) office of RMMCH, the Gauteng Health Research Committee (approval number GP_ 202208_002) and the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (approval number M220848 MED 22-07-073).

This retrospective descriptive study utilised anonymised data collected as part of routine clinic procedures with consent obtained from parents for data sharing. To ensure patient anonymity and confidentiality, no identifying information was included when extracting, analysing and reporting the study findings.

RESULTS

A total of 267 patients were identified and included in the study after screening 5027 electronic files in the clinic's database system (Figure 1). The study population consisted of 154 patients who were linked to care or referred to the clinic between 01 March 2018 to 28 February 2019 (pre-COVID era), and 113 patients who were linked to care between 01 March 2020- 28 February 2021 (COVID era).

There were 41 fewer patients linked to care during the COVID era compared to the pre-COVID era (154 in pre-COVID and 113 in COVID era) which was a 27% decline. The decline in the number of patients linked to care during the COVID-era was particularly notable at the onset of the South African national lockdown. Although there was a brief recovery in the following weeks, there were subsequent declines during the beta and delta COVID-19 waves in South Africa (Figure 2).

Demographics at presentation

Table 1 provides a summary of the key characteristics of the patients at their first visit to the ESRU HIV clinic or upon enrolment into care through the hospital's VTP program (previously known as the PMTCT program) or referral of patients admitted to the wards. As shown in Table 1, many of the patients linked to care in both the study periods were children under the age of 5 years. Specifically, 117 patients (76%) were children under the age of 5 years in the pre-COVID era while 85 patients

(75%) were children under the age of 5 years in the COVID era. There was no significant difference in the age at presentation between the two eras (Figure 3, Table 1). During both the pre-COVID era and the COVID era, the outpatient department served as the primary referral source for enrolling HIV-infected children and adolescents into HIV care. In the pre-COVID era, 78 patients (51%) were referred from the outpatient department, while in the COVID era, 61 patients (54%) were referred from the same department. However, there was a concerning decline in the number of patients linked to care through the VTP program during the COVID era. Only 20 patients (18%) were referred through the VTP program in the COVID era, compared to 45 patients (29%) in the pre-COVID era. Because of this, there was a proportional increase in the number of referrals from the inpatient departments during the COVID era and these children were acutely ill and required hospitalisation. We had a total of 32 patients (28%) referred from inpatient departments during the COVID era, in comparison to 31 patients (20%) during the pre-COVID era. In the pre-COVID era, we recorded 25 patients (16%) who were transferred in from other healthcare facilities, already diagnosed and on treatment and 129 were new patients (84%). Similarly, in the COVID era, there were 20 patients (18%) who were transferred in, and 93 patients (82%) were new patients.

The duration from the first diagnosis of HIV infection to the first visit in both study periods was commonly within 7 days of diagnosis. However, it is noteworthy that in the COVID era, there were 33 patients (29%) who presented more than 7 days after being diagnosed with HIV infection compared to 39 (25%) in the pre-COVID era. This was predominately observed among outpatients, who may have faced multiple constraints in accessing care during the COVID era.

Clinical Features

Excluding neonates, we observed that there was no significant difference in anthropometry between patients at presentation in the two study periods. Our findings revealed that many of the patients in both study periods were underweight for age (UWFA), with approximately 54% of patients in the pre-COVID era and 53% of patients in the COVID era falling into this category.

Furthermore, although not significant it is important to note that there were more patients in the COVID era (41%) who presented with advanced HIV disease and co-infections necessitating hospital admission and in-hospital treatment when compared to 36% of patients in the pre-COVID era. This is consistent with the observed general population's health seeking behaviour during the pandemic where majority of people who sought healthcare, specifically hospital care where individuals with severe symptoms and life threatening conditions.^{13, 14}

Outcomes

Table 2 provides a summary of the outcomes of the patients one year after their first visit. In the pre-COVID era, there were a total of 9 deaths, including one non-HIV-related early neonatal death. In the COVID era, there were 10 deaths, including two neonatal deaths that were also not HIV-related. The median age at death in the pre-COVID era was 3 months (with a mean of 21 months), and the median number of days from the first visit to death was 14 days (with a mean of 20 days). In comparison, in the COVID era, the median age at death was 8 months (with a mean of 11 months) and the median number of days from first visit to death was 18 days (with a mean of 83 days). There was no difference in poor outcome (combining loss to follow-up and death) between the groups. In both the pre-COVID and COVID era there was a 23% chance of death or loss to follow-up by 12 months (log-rank test $p=0.93$).

Regarding loss to follow-up, seven percent of patients in the pre-COVID era were lost to follow-up at the end of their first year in care, compared to 11% of patients in the COVID era which was not significantly different. In the pre-COVID era 27 (18%) patients missed their appointments by 30 days or more, including up to 90 days, compared to 9 (8%) patients in the COVID era.

In the pre-COVID era, 50 patients (34%) achieved viral suppression (VL <1000 copies/ml) at six months post-initiation of ART, while in the COVID era, 31 patients (29%) achieved viral suppression during the same period. One year post the first visit, it was concerning to note that only 41% of the pre-COVID era patients who were retained in care achieved viral suppression (viral load of less than 1000

cells/ml). Among these patients, only a half of them had a viral load of less than 50 copies/ml which is a stricter definition of viral suppression. Similarly, in the COVID era, 43% of the patients in care achieved viral suppression (VL < 1000 copies/ml) at one year post the first visit, and almost half of them had a viral load less than 50 copies/ml.

DISCUSSION

The findings of this study provide valuable insights into the impact of the COVID-19 pandemic on HIV care at the RMMCH HIV Clinic (ESRU), which is one of the larger Johannesburg clinics dedicated to providing HIV services to children and adolescents in Gauteng and has over 1600 children in active care. The clinic receives most of its patients from drainage clinics and the hospital's outpatient department. Patients are also referred via the hospital's VTP program and via in-patient referrals. Any disruption to this referral pathway negatively impacts the enrolment of patients into HIV care at this clinic.

The goals of HIV care are to; identify people living with HIV, initiate them on treatment, maintain viral suppression and sustain them on treatment. Maintaining viral suppression in people living with HIV decreases their risk of opportunistic infections, morbidity and mortality with an overall improvement in their quality of life.¹⁵

We observed a significant decline in the enrolment of children and adolescents into HIV care during the COVID-19 pandemic, but further research is needed to discern the pandemic's specific impact. Keeping children in care was an ongoing concern that was already noted before the pandemic. Although there was no statistical difference, approximately 11% of patients were lost to follow up during the COVID era. This is a significant number. Missed visits were less during the pandemic than before. A possible reason for this could be that there was less movement of patients between provinces due to lockdowns or a form of improved health-seeking behaviour amongst people living with HIV during the COVID pandemic period.

South Africa has recorded a significant decline in the number of new HIV infections among children since 2005. Between 2016 and 2021 (a five-year period), the annual percentage decline of new HIV infections in children ranged from 5% to 18.3% at the end of 2021. However, at the end of 2022 we recorded for the first time in 17 years a 5.2% increase in number of new infections amongst children.¹⁶

We reported a 27% decline in the number of children and adolescents enrolled in care during the first year of the COVID-19 pandemic compared to the year before the pandemic. Additionally, there was a decline in the number of neonates accessing care through the hospital's VTP program ($p=0.025$). The decline was primarily observed during the first four months of the pandemic and at the peak of subsequent waves, with children under the age of five years being the most affected. A decline in enrolment could also be due to fewer infants and children becoming HIV-infected due to better VTP programs, however, a 27% decline is greater than the expected decline from fewer new HIV infections due to improved vertical transmission prevention programs.

These findings have the potential to impede the progress already made in South Africa towards meeting the United Nation's sustainable development goal 3.2, which aims to end preventable deaths of newborns and children under the age of five by the year 2030.⁷ Our finding highlights that the vertical transmission prevention programme is vulnerable and needs to be strengthened such that future critical events similar to COVID have a lesser impact.

A national decline in HIV testing was reported during the first year of the pandemic, with Gauteng being one of the provinces most affected. Similar studies conducted in other Low and Middle-income Countries (LMIC) have also demonstrated a decrease in the number of primary healthcare attendances and utilisation of HIV care and ART services.^{3, 11, 17, 18} These findings underscore the need to intensify HIV testing and prevention efforts in children and adolescents during all healthcare consultations and as part of community outreach programs. These measures will help bridge the gap created by the early stages of the pandemic and most importantly, work towards achieving the United Nation's Sustainable Development Goal of ending preventable deaths and eliminating AIDS as a public threat by the year 2030.¹

The decline in the number of neonates enrolled in care through the VTP program can be attributed to the global and national decrease in attendance for antenatal care services during the pandemic.^{19, 20} A study conducted in South Africa reported a reduction in antenatal care attendance during the initial four months of the pandemic. Interestingly, the study also noted an increase in deliveries in public health facilities during the same period.¹⁴ These findings raise concerns regarding the effectiveness of HIV testing in our healthcare facilities during periods of significant strain, such as the pandemic when there is a surge in the number of people accessing healthcare services. This disruption of antenatal HIV testing and the increased number of neonates diagnosed with HIV infection in the outpatient setting suggests that pregnant women living with HIV before the pandemic had a higher rate of vertical transmission during the pandemic which possibly alludes to poorer maternity services during the COVID-19 pandemic.

We may have missed diagnosing mothers living with HIV and their exposed children during the COVID era, emphasising the importance of HIV awareness and testing for all children and mothers presenting for child health care services. This is particularly crucial for children born during the first year of the COVID-19 pandemic. By promoting awareness and considering every mother and child healthcare visit as an opportunity to offer HIV testing, we can uphold our commitment to meeting the WHO 95-95-95 testing and treatment targets.

Paediatric HIV care is largely dependent on caregivers, whom we rely on to assist with administering medication and adherence to treatment plans. However, despite improvements in accessibility and medication formulations, high rates of loss to follow-up and poor adherence are still being reported among children and adolescents living with HIV.²⁰ Children under the age of five years are particularly at risk of loss to follow-up.²⁰ Our findings indicate that loss to follow-up is most pronounced during the first six months of enrolment into care in both study periods. This highlights the urgency for our HIV health care centres and providers to prioritise the improvement of current HIV care strategies. Additionally, there is a need for the development of strategies that focus on early ART care including support for children and adolescents who are newly enrolled in HIV care.

Studies investigating the high rate of loss to follow-up and non-suppression in HIV-infected children have reported a range of factors contributing to loss to follow-up across different groups. These studies also highlight that a significant proportion of children enrolling into HIV care fail to achieve viral suppression and are subsequently lost to follow-up shortly after initiating ART which was also reported to be true during the pandemic.^{20, 21} Among younger children, there is an increased risk of loss to follow-up during the first six months following the initiation of ART. The most important factors contributing to this trend are often related to caregivers.²⁰ In contrast, the adolescent group presents with different factors including; lack of support, stigma, school absenteeism, unpleasant clinic visits and the impact of living with HIV on their mental health.²²

South African guidelines applicable during the two study periods stipulated viral load testing at six months, twelve months, and every twelve months if the viral load was below 50 copies/ml. Consequently, every child living with HIV should have at least one viral load test a year. However, viral load testing in children remains inadequate in South Africa.²⁰

A study conducted in KwaZulu-Natal found that the COVID-19 pandemic did not impact the frequency of viral load testing or viral load suppression rates. However, they observed a decreasing trend in viral load testing even before the pandemic. This further reinforces the need for the development of strategies to address early ART care and support for children and adolescents.²³

Our study revealed that there was no significant difference in treatment outcomes during the two study periods. The percentage of patients lost to follow-up was similar, as were the rates of viral suppression. Furthermore, no notable difference in mortality rates was observed. It is crucial to recognize that the true effects of the pandemic on HIV care in children and adolescents may be understated during this immediate period. These effects are expected to emerge over the next five years. Consequently, it is of utmost importance to enhance the delivery of HIV healthcare services to adequately address the anticipated surge in demand that may arise in the coming years.²⁴

The COVID-19 pandemic has had a profound impact on the healthcare sector as well as various other sectors globally. It has provided us with valuable lessons, highlighting the importance of preparedness and the need to establish and maintain robust systems that guarantee healthcare access and service delivery while safeguarding the vulnerable population during periods of heightened healthcare demand.²⁵

Limitations

This study is based on one centre and uses data from one year prior to the pandemic which may not be a true reflection of other years prior to the COVID-19 pandemic. Due to the routine nature of the clinic, there is missing data making some conclusions more difficult to make.

CONCLUSION

The COVID-19 pandemic has had a detrimental impact on the enrolment of children and adolescents into HIV healthcare services, primarily due to restricted access to healthcare and disruptions in HIV care delivery. This challenge can be attributed in part to insufficient human resources dedicated to HIV care, the healthcare system's inability to handle sudden surges in demand, and the social implications created by the pandemic, including income loss, food insecurity, and fear of contracting the virus. The pandemic has also shed light on existing challenges in HIV care, presenting an opportunity for our nation to strengthen HIV services and strive towards ending AIDS as a public health threat.

ACKNOWLEDGEMENTS

We would like to acknowledge Mr Malose Lebelo for his assistance with the data in the clinic. The data collected at the clinic is supported by the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health, as part of the International epidemiology Databases to Evaluate AIDS Southern Africa collaboration (award number U01AI069924). We acknowledge all children, adolescents and parents attending our clinic.

REFERENCES

1. UNAIDS. UNAIDS DATA 2020 [cited 2021 23 October 2021]. Available from: www.unaids.org.
2. SA S. Mortality and causes of death in South Africa, 2017: Findings from death notification 2017 [updated 2020; cited 2023 12 March 2023]. Available from: <https://www.statssa.gov.za/publications/P03093/P030932017.pdf>.
3. Dunlop JL, Lilian RR, Tait CL, Mabitsi M, Struthers H, McIntyre JA, et al. Where have we come from and where are we going? The paediatric HIV programme in Johannesburg, South Africa, from 2004 to 2018: A retrospective analysis of programme trends. *S Afr Med J*. 2022;112(5):328-34.
4. UNAIDS. 2025 AIDS Targets 2023 [cited 2023 27 March 2023]. Available from: https://www.unaids.org/en/topics/2025_target_setting.
5. Nations U. Sustainable Development Goals [cited 2024 07 July 2024]. Available from: <https://sdgs.un.org/goals>.
6. UNAIDS. UNAIDS DATA 2022 South Africa 2022 [cited 2023 27 March 2023]. Available from: https://www.unaids.org/sites/default/files/media_asset/data-book-2022_en.pdf.
7. Unicef. Key demographic indicators 2023 [cited 2023 30 March 2023]. Available from: <https://data.unicef.org/country/zaf/>.
8. Medina N, Alastruey-Izquierdo A, Bonilla O, Ortíz B, Gamboa O, Salazar LR, et al. Impact of the COVID-19 pandemic on HIV care in Guatemala. *International Journal of Infectious Diseases*. 2021;108:422-7.
9. Abdool Karim Q, Abdool Karim SS. COVID-19 affects HIV and tuberculosis care. *Science*. 2020;369(6502):366-8.
10. Jensen C, McKerrow NH. Child health services during a COVID-19 outbreak in KwaZulu-Natal Province, South Africa. *S Afr Med J*. 2020;111(2):114-9.
11. Dorward J, Khubone T, Gate K, Ngobese H, Sookrajh Y, Mkhize S, et al. The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis. *Lancet HIV*. 2021;8(3):e158-e65.
12. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-81.
13. Jensen C, Yannigan Y, Mafanya N, Majozi N, Martin T, Mnguni T, et al. Patterns of disease on admission to children's wards and changes during a COVID-19 outbreak in KwaZulu-Natal Province, South Africa. *S Afr Med J*. 2022;112(4):279-87.
14. Pillay Y, Pienaar S, Barron P, Zondi T. Impact of COVID-19 on routine primary healthcare services in South Africa. *S Afr Med J*. 2021;111(8):714-9.
15. Aduagna A, Azanaw J, Melaku MS. The Effect of COVID-19 on Routine HIV Care Services from Health Facilities in Northwest Ethiopia. *HIV/AIDS (Auckland, NZ)*. 2021;13:1159.
16. UNAIDS. Trends of new HIV infections 2021 [cited 2023 15 March 2023]. Available from: <https://www.unaids.org/en/resources/fact-sheet>.
17. Aduagna A, Azanaw J, Sharew Melaku M. The Effect of COVID-19 on Routine HIV Care Services from Health Facilities in Northwest Ethiopia. *HIV AIDS (Auckl)*. 2021;13:1159-68.

18. Tessema GA, Kinfu Y, Dachew BA, Tesema AG, Assefa Y, Alene KA, et al. The COVID-19 pandemic and healthcare systems in Africa: a scoping review of preparedness, impact and response. *BMJ Glob Health*. 2021;6(12).
19. Townsend R, Chmielewska B, Barratt I, Kalafat E, van der Meulen J, Gurol-Urganci I, et al. Global changes in maternity care provision during the COVID-19 pandemic: A systematic review and meta-analysis. *EClinicalMedicine*. 2021;37:100947.
20. van Liere G, Lilian R, Dunlop J, Tait C, Rees K, Mabitsi M, et al. High rate of loss to follow-up and virological non-suppression in HIV-infected children on antiretroviral therapy highlights the need to improve quality of care in South Africa. *Epidemiol Infect*. 2021;149:e88.
21. Shi L, Tang W, Hu H, Qiu T, Marley G, Liu X, et al. The impact of COVID-19 pandemic on HIV care continuum in Jiangsu, China. *BMC Infect Dis*. 2021;21(1):768.
22. van Wyk BE, Davids LC. Challenges to HIV treatment adherence amongst adolescents in a low socio-economic setting in Cape Town. *South Afr J HIV Med*. 2019;20(1):1002.
23. Mathamo A, Naidoo KL, Dorward J, Archary T, Bottomley C, Archary M. COVID-19 and HIV viral load suppression in children and adolescents in Durban, South Africa. *South Afr J HIV Med*. 2022;23(1):1424.
24. Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. *Lancet Glob Health*. 2020;8(9):e1132-e41.
25. Siedner MJ, Kraemer JD, Meyer MJ, Harling G, Mngomezulu T, Gabela P, et al. Access to primary healthcare during lockdown measures for COVID-19 in rural South Africa: an interrupted time series analysis. *BMJ Open*. 2020;10(10):e043763.
26. Abdool-Karim Q, Abdool-Karim SS. The evolving HIV epidemic in South Africa. *Int J Epidemiol*. 2002;31(1):37-40.
27. UNAIDS. UNAIDS DATA 2021 South Africa 2021 [cited 2023 27 March 2024]. Available from: <https://www.unaids.org/en/regionscountries/countries/southafrica>.
28. Vrazo AC, Golin R, Fernando NB, Killam WP, Sharifi S, Phelps BR, et al. Adapting HIV services for pregnant and breastfeeding women, infants, children, adolescents and families in resource-constrained settings during the COVID-19 pandemic. *J Int AIDS Soc*. 2020;23(9):e25622.
29. Araujo LA, Veloso CF, Souza MC, Azevedo JMC, Tarro G. The potential impact of the COVID-19 pandemic on child growth and development: a systematic review. *J Pediatr (Rio J)*. 2021;97(4):369-77.
30. Castel AD, Wilbourn B, Magnus M, Greenberg AE. SARS-CoV-2 and HIV: Epidemiology, Treatment, and Lessons Learned from HIV. *AIDS Rev*. 2020;22(3):133-42.
31. Coker M, Folayan MO, Michelow IC, Oladokun RE, Torbunde N, Sam-Agudu NA. Things must not fall apart: the ripple effects of the COVID-19 pandemic on children in sub-Saharan Africa. *Pediatr Res*. 2021;89(5):1078-86.
32. Grimsrud A, Wilkinson L. Acceleration of differentiated service delivery for HIV treatment in sub-Saharan Africa during COVID-19. *J Int AIDS Soc*. 2021;24(6):e25704.
33. Kanwugu ON, Adadi P. HIV/SARS-CoV-2 coinfection: A global perspective. *J Med Virol*. 2021;93(2):726-32.
34. Lesko CR, Bengtson AM. HIV and COVID-19: Intersecting Epidemics With Many Unknowns. *Am J Epidemiol*. 2021;190(1):10-6.

- 515 35. M D. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a population
516 Cohort Study from the Western Cape Province, South Africa. *Clinical Infectious Diseases*.
517 2021;73:2005 - 15.
- 518 36. Abdool Karim Q, Baxter C. COVID-19: Impact on the HIV and Tuberculosis Response,
519 Service Delivery, and Research in South Africa. *Current HIV/AIDS Reports*. 2022:1-8.
- 520 37. Armbruster M, Fields EL, Campbell N, Griffith DC, Kouoh AM, Knott-Grasso MA, et al.
521 Addressing health inequities exacerbated by COVID-19 among youth with HIV: expanding
522 our toolkit. *Journal of Adolescent Health*. 2020;67(2):290-5.
523




Figure 1: Selection Process of The Study Population- From Initial Screening to Final Cohort

Values represent absolute number of patients
ESRU= Empilweni Services and Research Unit.




Figure 2: Total number of patients who presented to the HIV clinic during the two study periods; 2018- 2019 (pre-COVID era) and 2020- 2021 (COVID era)

Number of patients represented as absolute numbers.

Red interval corresponds to first COVID-19 wave in South Africa (D614G variant)

Yellow interval corresponds to second COVID-19 wave in South Africa (Beta variant)




Figure 3: Age of the patients at presentation to the HIV clinic in age groups during the two time periods; 2018-2019 (pre-COVID era) and 2020- 2021 (COVID era)

Number of patients represented in absolute numbers.

554 **Table 1:** First visit demographics and clinical characteristics of patients at
555 presentation

		2018 - 2019	2020 - 2021	P Value
Total number of Patients		154	113	
Referral Site	VTP program	45 (29%)	20 (18%)	0.059
	Inpatients	31 (20%)	32 (28%)	
	Outpatients	78 (51%)	61 (54%)	
Age at Diagnosis	≤ 4 weeks	45 (29%)	34 (30%)	0.66
	1- < 6 months	31 (20%)	27 (24%)	
	6- < 12 months	13 (8%)	9 (8%)	
	1- < 5 years	35 (23%)	18 (16%)	
	5- < 10 years	19 (12%)	16 (14%)	
	> 10 years	11 (8%)	9 (8%)	
Duration from diagnosis to 1 st visit	Transfer In	25 (16%)	20 (18%)	0.75
	Early	90 (59%)	60 (53%)	0.54
	Late	39 (25%)	33 (29%)	
Age at Presentation	≤ 4 weeks	38 (25%)	28 (25%)	0.91
	1- < 6 months	26 (16%)	22 (19%)	
	6- < 12 months	15 (10%)	13 (12%)	
	1- < 5 years	38 (25%)	22 (19%)	
	5- < 10 years	20 (13%)	17 (15%)	
	> 10 years	17 (11%)	11 (10%)	
Anthropometry	Neonates	*38 (25%)	*28 (25%)	1.0
	UWFA	63 (54%)	45 (53%)	
	NWFA	53 (46%)	40 (47%)	
WHO Clinical staging of HIV/AIDS	Neonates	*38 (25%)	*28 (25%)	0.98
	Mild disease	48 (48%)	34 (46%)	0.74
	Advanced disease	51 (52%)	40 (54%)	
Immunological Stage	Mild immunosuppression	70 (46%)	52 (46%)	1.0
	Advanced immunosuppression	59 (38%)	44 (39%)	
	Not staged	25 (16%)	17 (15%)	

Numbers in absolute numbers

VTP = Vertical Transmission Prevention program

Transfer in = participant already initiated on antiretroviral therapy at presentation

Early duration from diagnosis to 1st visit = diagnosed less than 8 days ago at presentation

Late duration from diagnosis to 1st visit = diagnosed 8 or more days ago at presentation

UWFA= Underweight for age, weight for age less than -2 SD for age and sex

NWFA= Normal weight for age, weight for age between -2 and +2 SD for age and sex

WHO = World Health Organisation

* Neonates which have been excluded from the rest of the population's calculations for the value

Table 2: Treatment Outcomes of patients enrolled in care during the two study periods; 2018-2019 (pre-COVID) and 2020- 2021 (COVID) at one year post enrolment into care

			2018 - 2019	2020 - 2021	P Value
Total number of Patients			154	113	
Outcome at one year post enrolment into care	Lost to follow-up		11 (7%)	12 (11%)	0.53
	Death		9 (6%)	10 (9%)	
	Transferred out		32 (21%)	23 (20%)	
	In care		102 (66%)	68 (60%)	
Loss to Follow-Up	0 – 3 months		5 (46%)	6 (50%)	0.73
	3 – <6 months		2 (18%)	3 (25%)	
	≥6 – 12 months		4 (36%)	3 (25%)	
Missed appointments in the first year of ART	30 Days		50 (32%)	24 (21%)	0.043
	90 Days		27 (18%)	9 (8%)	0.024
Viral Load	6 Months	<50 copies/ml	21 (14%)	14 (13%)	0.74
		<1000 copies/ml	29 (20%)	17 (16%)	
	12 Months	< 50 copies/ml	21 (21%)	15 (22%)	0.74
		<1000 copies/ml	20 (20%)	14 (21%)	

Table 3: Neonatal diagnosis demographics and treatment outcomes

		2018 - 2019	2020 - 2021	P Value
Total number of Patients		38	28	
Referral Site	VTP program	36 (94%)	17 (61%)	0.0025
	Inpatients	1 (3%)	3 (11%)	
	Outpatients	1 (3%)	8 (28%)	
Place of Birth	RMMCH	36 (94%)	19 (68%)	0.0038
	Gauteng Clinic	2 (6%)	9 (32%)	
Maternal diagnosis	Before Pregnancy	6 (16%)	11 (39%)	0.065
	During Pregnancy	25 (66%)	10 (36%)	
	At Delivery / After pregnancy	7 (18%)	7 (25%)	
Duration from diagnosis to 1 st visit	Early	35 (92%)	23 (82%)	0.22
	Late	3 (8%)	5 (18%)	
	Transfer In	0 (0%)	0 (0%)	NA
Age at Presentation	≤ 7 days	30 (79%)	20 (71%)	0.64
	8 – 14 days	4 (11%)	3 (11%)	
	15 – 21 days	2 (5%)	4 (14%)	
	22 – 28 days	2 (5%)	1 (4%)	
Birthweight	≥4000g	0 (0%)	0 (0%)	0.54
	2500 - <4000g	24 (63%)	19 (68%)	
	1500 - <2500g	13 (34%)	7 (25%)	
	<1500g	1 (3%)	2 (7%)	
Weight at 1 st visit in relation to birthweight	Appropriate	37 (97%)	27 (96%)	1.0
	Inappropriate	1 (3%)	1 (4%)	
Outcome at 1 year post ART initiation	In care	25 (66%)	15 (54%)	0.56
	Transferred out	5 (13%)	3 (10%)	
	Loss to follow-up	5 (13%)	5 (18%)	
	Death	3 (8%)	5 (18%)	
Viral load of patients in care	6 months	<50 copies/ml	2 (8%)	0.22
		<1000 copies/ml	9 (36%)	
		Not done	14 (56%)	
	12 months	<50 copies/ml	2 (8%)	0.51
		<1000 copies/ml	5 (20%)	
		Not done	18 (72%)	
Loss to Follow-up	0 - <3 months	2 (40%)	2 (40%)	1.0
	3 – <6 months	2 (40%)	2 (40%)	
	≥6 – 12 months	1 (20%)	1 (20%)	

VTP = Vertical Transmission Prevention program

RMMCH = Rahima Moosa Mother and Child Hospital

Early duration from diagnosis to 1st visit = diagnosed less than 8 days ago at presentationLate duration from diagnosis to 1st visit = diagnosed 8 or more days ago at presentation

Appropriate weight = ≥10g/kg/day weight gain if neonate >10 days, Inappropriate weight = weight less than birthweight or <10g/kg/day weight gain if neonate >10 days

ART= Antiretroviral Therapy



R49 Dr M Phasha

**HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL)
CLEARANCE CERTIFICATE NO. M220848**

NAME:
(Principal Investigator)

Dr M Phasha

DEPARTMENT:

School of Clinical Medicine
Department of Paediatrics and Child Health
Medical School
University

PROJECT TITLE:

*Impact of the COVID- 19 pandemic on HIV care in a
paediatric and adolescent ARV Clinic in Johannesburg:
A retrospective cohort study*

DATE CONSIDERED:

2022/08/26

DECISION:

Approved unconditionally

CONDITIONS:**NOTE:**

If contact information regarding student study participants is required,
please contact the Registrar's office - <Nicoleen.Potgieter@wits.ac.za>

SUPERVISOR:

Dr G Sorour and Professor K-G Technau

APPROVED BY:

Dr CB Penny
Dr CB Penny, Chairperson, HREC (Medical)

DATE OF APPROVAL:

2022/11/21

This Clearance Certificate is valid for 5 years from the date of approval. An extension may be applied for.

DECLARATION OF INVESTIGATORS

To be completed in duplicate and **ONE COPY** returned to the Research Office secretariat on the 3rd floor, Phillip Tobias Building, Parktown, University of the Witwatersrand, Johannesburg.

I/we fully understand the conditions under which I am/we are authorized to carry out the above-mentioned research and I/we undertake to ensure compliance with these conditions. Should any departure be contemplated from the research protocol as approved, I/we undertake to submit details to the Committee. **I agree to submit a yearly progress report.** When a funder requires annual re-certification, the application date will be one year after the date when the study was initially reviewed. In this case, the study was initially reviewed in **August** and therefore reports and re-certification will be due in the month of **August** each year. Unreported changes to the study may invalidate the clearance given by the HREC (Medical).

Signature of Principal Investigator

Date

RESEARCH PROTOCOL

Title:

Impact of the COVID-19 Pandemic on HIV Care in a Paediatric and Adolescent ARV Clinic in Johannesburg:
A Retrospective Cohort Study

Student: Dr Masello Phasha

Student Number: 358603

Degree: Master of Medicine in Paediatrics and Child Health

Supervisors:

Dr Gillian Sorour, Paediatric Infectious Diseases, Rahima Moosa Mother and Child Hospital

Assoc. Prof. Karl-Günter Technau, Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital

606	TABLE OF CONTENTS	
607	<u>INTRODUCTION</u>	<u>28</u>
608	<u>LITERATURE REVIEW</u>	<u>31</u>
609	HIV SERVICES DURING THE COVID-19 PANDEMIC	31
610	CHILD HEALTHCARE DURING THE COVID-19 PANDEMIC	32
611	COVID-19 AND HIV CO-INFECTION	33
612	<u>AIMS AND OBJECTIVES</u>	<u>35</u>
613	AIMS	35
614	OBJECTIVES	35
615	<u>METHODS</u>	<u>36</u>
616	STUDY DESIGN	44
617	STUDY POPULATION	37
618	DATA COLLECTION	31
619	DATA ANALYSIS	31
620	CHARACTERISTICS OF NEW PATIENTS	38
621	ABSOLUTE NUMBER OF NEW PATIENTS	38
622	DURATION FROM DIAGNOSIS TO INITIATION OF ART	39
623	AGE AT PRESENTATION AND DEMOGRAPHIC FEATURES	39
624	CLINICAL FEATURES AT PRESENTATION	39
625	ASSESSMENT OF HIV CARE	39
626	ADHERENCE TO APPOINTMENTS AND LOSS TO FOLLOW UP	39
627	LEVEL OF VIRAL SUPPRESSION	40
628	<u>ETHICS</u>	<u>49</u>
629	<u>STUDY TIMELINE</u>	<u>42</u>
630	GANT CHART	42
631	<u>BUDGET</u>	<u>42</u>
632	<u>REFERENCES</u>	<u>45</u>
633	<u>APPENDIX 1</u>	<u>46</u>
634	<u>APPENDIX 2</u>	<u>47</u>
635	<u>APPENDIX 3</u>	<u>48</u>

636

637 **NOMENCLATURE**

638

639 AIDS - Acquired Immunodeficiency Syndrome

640 ART - Antiretroviral Therapy

641 ARV - Antiretroviral

642 COVID- 19 - Coronavirus disease 2019

643 ELISA - Enzyme- linked immunosorbent assay

644 ESRU - Empilweni Services and Research unit

645 HIV - Human Immunodeficiency Virus

646 JHB - Johannesburg

647 PCR - Polymerase Chain Reaction

648 PLWHIV - People Living with HIV

649 PMTCT - Prevention of Mother to Child Transmission

650 RMMCH - Rahima Moosa Mother and Child Hospital

651 SA - South Africa

652 SARS-CoV-2 - Severe Acute Respiratory Syndrome Coronavirus 2

653 TB - Tuberculosis

654 VL - Viral load

655 WHO - World Health Organisation

656

657

658

659

INTRODUCTION

South Africa reported the first case of Human Immunodeficiency Virus (HIV) infection in 1982 when it was initially thought to be limited to homosexuals and recipients of blood transfusions ²⁶.

The epidemic became of particular concern to the paediatric population in the 1990s when HIV was first detected in pregnant women and there was subsequent spread to the paediatric population mainly through vertical transmission from mother to child during the antenatal, perinatal and post-natal period mainly through breastfeeding ²⁶.

South Africa has the biggest HIV epidemic in the world with 7.8 million (>12%) of its 59 million population documented to be living with HIV at the end of 2020. Globally there are now approximately two million children living with HIV and it is reported that 310 000 of these children (age 1- 14 years) are living in South Africa and that less than half of them are on antiretroviral therapy (ART) ²⁷.

There have been significant advances in the prevention of new HIV infections in children mainly through the prevention of mother to child transmission of HIV program (PMTCT), with 97% of HIV infected pregnant women receiving ART for PMTCT in 2020 and over 52000 new HIV infections averted due to PMTCT ²⁷.

HIV related illnesses however are still among the leading causes of infant morbidity and mortality in our country ².

In March 2020, South Africa recorded its first case of the novel Coronavirus in Natal. The government soon after instituted a national lockdown on 27 March 2020. The aim of the lockdown was to curb transmission of the virus now called SARS-CoV-2

686 and thereby protect those most vulnerable to severe disease – the elderly and
687 immunocompromised- and to protect healthcare services from being overwhelmed.
688 The lockdown was unfortunately accompanied by unforeseen negative
689 consequences for the provision of other health care services and for the well-being
690 of children who were thankfully largely spared severe disease due to SARS-CoV-2
691 infection ⁹.

692

693 At the beginning of the COVID-19 pandemic national lockdown there was a shift of
694 focus and resources from most health care services to the prevention, containment,
695 and management of SARS-CoV-2 infections. This resulted amongst other things in
696 pregnant and breastfeeding women and at-risk children missing routine HIV testing
697 and initiation onto antiretroviral therapy when indicated ²⁸.

698 The disruption of child health and antenatal care services by the COVID-19
699 pandemic especially during the lockdown months meant that fewer children had
700 access to basic primary health care services with possible reversal of milestones in
701 the advancements of HIV care in South Africa ²⁸.

702

703 Epidemics in the past such as Ebola, Smallpox, Polio, HIV and Swine flu have
704 resulted in high levels of anxiety in parents and patients due to concerns of
705 becoming infected with subsequent severe disease or even death. They indirectly
706 affect children's development and health due to parents socially isolating their
707 children and not attending routine clinic visits with resultant negative consequences
708 to schooling and to mental and physical health ²⁹. It is possible that the COVID-19
709 pandemic has had a similar effect especially because of the high morbidity and
710 mortality rates reported globally.

711

712 For children living with HIV the initial concern that people living with HIV may be at
713 an increased risk of suffering severe disease from COVID-19 infection, with resultant
714 restriction of movement and other lockdown measures has put their health at risk ³⁰.
715 Their wellbeing has been compromised either directly by them limiting access to
716 healthcare services or indirectly by the effects of the pandemic on food security and
717 the inequalities of poverty ³¹.

718

719 Retention in care has been reported to be a major issue in the management of HIV
720 infection in children even before the COVID-19 pandemic despite treatment being
721 widely available and accessible ¹⁶. It is presumed that the co-existence of the HIV
722 epidemic with the COVID-19 pandemic has resulted in a significant compromise in
723 HIV care of children and that the effects maybe noted for as long as the next 5 years
724 ³¹ .

725 The ongoing provision of HIV care services is important in ensuring the health of all
726 HIV infected individuals while working towards achieving the global 90:90:90 HIV
727 targets which are that 90% of people living with HIV know their status, 90% of them
728 are receiving ART and that 90% of those on ART are virally suppressed, to keep the
729 HIV epidemic controlled ³².

730 In a country such as South Africa which has such a high burden of children living
731 with HIV, the continued care and uptake of new patients should remain a priority
732 alongside the management of the pandemic.

733 It is therefore important to assess if the COVID-19 pandemic has had an impact on
734 HIV care in our paediatric population. The aim of this study is to highlight the

consequences of the COVID-19 pandemic and help guide future management strategies and policies.

LITERATURE REVIEW

HIV services during the COVID-19 pandemic

The COVID- 19 pandemic has impacted global health care service delivery and the redistribution of health care resources in response to the pandemic in an attempt to curb the spread of the SARS-Cov-2 infections has negatively affected health care including through impeding the access to primary public health programs, including HIV care services ³³.

There was an almost 50% decline of access to HIV services reported in KwaZulu-Natal during the pandemic with the largest decline reported at the beginning of the national lockdown which largely affected HIV testing and initiation of ART at local clinics ¹¹.

Approximately 28000 South African HIV community health workers were diverted from their HIV outreach programs to be part of the COVID-19 symptoms screening teams. This left a notable gap in the HIV care services in the communities during the initial period of the COVID-19 pandemic in South Africa ⁹.

In an article that analysed differentiated service delivery for HIV treatment during the COVID-19 pandemic, authors found that the pandemic has mostly affected newly diagnosed patients including their access to HIV prevention services, testing, and initiation onto ART ³².

However, little data is available on the effect of the Covid-19 pandemic on HIV care services in children.

Child healthcare during the Covid-19 pandemic

The ongoing health care of children is important as we work towards achieving the Sustainable Development Goals which include decreasing under 5 mortality and achieving good health for all. The effects of the Covid-19 pandemic on child healthcare have been observed throughout communities in sub-Saharan Africa. The greatest impact is thought to have been felt by children from poorer communities ³¹.

The institution of the national lockdown in South Africa and the closure of schools as part of the measures to manage the pandemic posed an increased risk of morbidity and mortality from infectious diseases in children. Child health care programs were affected, including school programs that are aimed at prevention, screening, and management of vaccine preventable infectious diseases amongst children ³¹.

During this lockdown period, children who are dependent on meals provided at schools were exposed to hunger, malnutrition, poor growth, and development ²⁹.

Alongside the disruption of school services and food programs during the national lockdown, there was a noticeable decline of children's access to immunisations mainly because of missed appointments during isolation, relocation to homes outside of usual place of residence and by avoiding health facilities because of fear of contracting COVID-19 infection ³¹.

787 Children's immunisation visits provide important health care promotion opportunities
788 as during these visits in addition to actual administration of immunisations for
789 vaccine preventable diseases, children's growth is monitored and they are screened
790 for diseases including HIV testing and initiation of antiretroviral therapy where
791 necessary and appropriate.

792

793 The observed disruption of children's healthcare programs during the pandemic is
794 concerning and it can be presumed that we will notice a decline in the number of
795 newly diagnosed children accessing HIV care services during the pandemic period
796 when compared to the period prior to the pandemic. We can also expect to notice a
797 surge in morbidity and mortality from HIV related infections especially in newly
798 diagnosed HIV infected children who may have missed their clinic visits during the
799 COVID-19 pandemic's national lockdown in South Africa.

800

801 **Covid-19 and HIV co-infection**

802

803 The co-existence of the HIV epidemic and the COVID- 19 pandemic has challenged
804 the health care sector and revealed gaps in health care provision. HIV infection was
805 thought to be a risk factor for severe disease from SARS-Cov-2 infection at the
806 beginning of the pandemic largely because HIV causes immunosuppression ³⁴. A
807 study in the Western Cape showed that there was an increased mortality from
808 COVID-19 infection for adults living with HIV ³⁵.

809 Studies have been conducted to assess the interaction between COVID- 19 and HIV
810 but there is still insufficient data to establish the interaction and this gap highlights
811 the need for further research and the need to strengthen current HIV care services
812 ³⁶.

813

814 The goals of HIV care is to; identify people living with HIV, initiate them on treatment,
815 maintain viral suppression and to sustain them on treatment, we therefore need to
816 establish ways of maintaining these goals while dealing with the pandemic ¹⁵.

817

818 The youth living with HIV are reported to be facing multiple challenges during the
819 COVID- 19 pandemic, which include loss of income and mental health difficulties
820 which has affected their adherence to treatment ³⁷.

821 A study which looked at HIV and Covid disease found that in people living with HIV,
822 COVID- 19 infections rate were low and caused a mild disease course in people on
823 ART, virally suppressed and with CD4 count of more than 200cells/microlitre ³⁰.

824 A review found that there is currently no evidence to suggest that HIV infection puts
825 one at an increased risk for Covid-19 infection (6).

826 There is great anxiety experienced by people living with HIV in regards to their
827 presumed increased risk of severe COVID-19 disease, it is for this reason that we
828 will most probably find that there was a decline in follow up of old patients during the
829 pandemic.

830

831

AIMS AND OBJECTIVES

AIMS

To assess the impact of the COVID-19 pandemic on HIV care in the Paediatric and Adolescent ARV Clinic at Rahima Moosa Mother and Child Hospital (RMMCH) by comparing components of HIV care data of new patients retained in care before and during the pandemic.

OBJECTIVES

1. To compare the characteristics of new patients referred to the Paediatric and Adolescent ARV clinic at Rahima Moosa Hospital in the year before (March 2018 – March 2019) and the first year of the COVID-19 pandemic (March 2020 – March 2021) in terms of:

- a) Absolute numbers of new patients seen
- b) Duration from diagnosis and referral to initiation of ART and the reasons for delay where applicable
- c) Age at presentation
- d) Clinical features, anthropometry (WHZ BMI), WHO stage and immunological stage at presentation

2. To assess the first twelve months of care for patients initiated on ART in the same two periods above in terms of adherence to treatment plans and appointments, loss to follow up, level of viral suppression and mortality.

The working hypothesis of the study is that the COVID-19 pandemic has had a negative impact on HIV care in children and as a result we will most probably find

860 that we had a decline in numbers of patients newly diagnosed with HIV and referred
861 to the HIV clinic during the first year of the COVID-19 pandemic.

862

863 **METHODS**

864

865 **STUDY DESIGN**

866

867 The study will be a retrospective cohort study that aims to describe the changes in
868 patterns of HIV care at the Rahima Moosa paediatric HIV clinic during the COVID-19
869 pandemic when compared to time before the pandemic.

870 The study will draw its data from a prospectively collected database which is
871 maintained in the clinic.

872

873 **STUDY SITE**

874

875 The study will take place at the Rahima Moosa Mother and Child Hospital's
876 Paediatric HIV Clinic, also known as Empilweni Services and Research unit (ESRU)
877 which is one of the larger paediatric HIV clinics in South Africa that currently is
878 serving the majority of the Westrand, parts of Soweto and some of the north of
879 Johannesburg.

880

881 The clinic receives referrals from the paediatric and neonatal wards at RMMCH, the
882 hospital's outpatient's department and from the local clinics in its drainage areas.

883 The clinic ran uninterrupted during the COVID- 19 pandemic without any staff or drug
884 shortages.

885 The clinic provides multidisciplinary team management of patients. The team
886 includes the following professionals: doctors, nurses, social worker, dietician and

887 rehabilitative services from physiotherapy and occupational therapy where
888 necessary. The clinic manages neonates, children and adolescents living with HIV.
889 The adolescent clinic sees adolescents up until the age of 18 years and beyond if
890 needed, but for the purpose of this study only data of patients aged 0 – 18 years will
891 be included.

892 Adolescent patients seen at the clinic have been diagnosed at a younger age and
893 are almost all exclusively infected through vertical transmission.

894

895 The daily management services at the clinic include assessment of newly diagnosed
896 HIV infected patients alongside with their caregivers, initiation of HIV treatment,
897 regular follow up of patients on ART, including those on second and third line
898 treatment. The clinic also monitors for and manages patients with complications that
899 may arise.

900

901 **STUDY POPULATION**

902

903 The patients aged 0-18 years attending the ART clinic at Rahima Moosa hospital as
904 new referrals.

905

906 **INCLUSIONS**

907 1. Patients aged 0-18 years referred to and seen at the HIV clinic during the period
908 01 March 2018 – 01 March 2019 and 01 March 2020 – 01 March 2021.

909

910 **EXCLUSIONS**

911 1. Patients whose parents refused data sharing consent.

912

913

DATA COLLECTION

Data is collected from the patient's hospital records at every consultation and entered onto the ESRU database which is hosted on the University of the Witwatersrand REDCAP platform ¹².

An application will be made to the electronic gatekeeper to grant us access during the study period to collect the necessary data for the study which will be received in a de-identified format and exclusively used for the purposes of conducting the research study.

The data requested from the existing ESRU database for the identified patients who meet the study's inclusion criteria will be collected using a data collection sheet for each patient, see appendix 1 and appendix 2.

DATA ANALYSIS

Characteristics of new patients

The aim is to compare the characteristics of new patients referred to the clinic between the periods; March 2018 – February 2019 and March 2020 – February 2021 as follows:

Absolute number of new patients

We will quantify the actual number of how many new patients were seen from the clinic's database.

Duration from diagnosis to initiation of ART

We will measure the period from diagnosis to initiation of ART in days and classify depending on days from referral to presentation to the clinic or consultation in the ward if it was an inpatient referral. Patients will be categorized into two groups: early initiation (equals to or less than seven days) and late initiation (more than seven days).

Age at presentation and demographic features

We will note the age at presentation and categorize it in three groups: under one year (< 12 months), one to five years (12- 60 months) and above five years (> 60 months). Other demographic features will include gender and nature of caregiver (biological parent/ caregiver who is not the biological parents).

Clinical features at presentation

We will use weight for height standard deviations and mid upper arm circumference to classify each patient under 5 years of age and we will use BMI for patients above 5 years of age to assess their nutritional status.

Assessment of HIV care

The aim is to assess the response to HIV care for patients initiated on ART in the same two periods as follow:

Adherence to appointments and loss to follow up

We will assess the visit schedule for each patient and check if they have honoured appointments at the time they were scheduled to come, and if they missed the appointment we will determine how long after the scheduled date they presented.

979

980 Patients will be classified as:

981 1) Death (timing will be described)

982 2) Loss to follow-up (no visits after a certain date in the absence of transfer out)

983 Loss to follow-up will be categorized as

984 a) No linkage (no contact after the first interaction)

985 b) Early (first follow-up visit done but lost to follow-up before six months of
986 care)

987 c) Late (after six months of care)

988 3) No loss to follow up

989 a. Full attendance to visits

990 b. Poor visit attendance (a gap of > 30 days late for a scheduled appointment
991 at least once)

992

993 **Level of viral suppression**

994

995 We will use the identified patient's viral load (VL) results from the database to
996 assess:

997 1) VL at ART initiation where available

998 2) Compliance with VL testing schedule

999 3) Six and twelve month VL suppression rates (percentage with VL <1000 copies/ml
1000 and <50 copies/ml)

1001 4) Time to first VL <1000 copies/ml and <50 copies/ml

1002

1003 Descriptive statistics will be used to describe the data: Frequencies and percentages
1004 for categorical data and medians, and interquartile ranges for continuous data.

1005 When comparing the characteristics above between the groups, we will use t-test for
1006 continuous data and chi-square for categorical data. Kaplan Meier analysis will be
1007 done to compare death and loss to follow-up between the two periods.

1008
1009

1010
1011

1012 **ETHICS**

1013

1014 Permissions to conduct the research study at RMMCH will be requested from the
1015 hospital's CEO office and an application to conduct the study will be made to The
1016 Faculty Graduate Studies Committee and the Human Research Ethics committee of
1017 the University of the Witwatersrand.

1018 As this is a retrospective descriptive study, prospective patient consent to use the
1019 data will not be ascertained but the clinic has since 2008 implemented a routine data
1020 sharing consent for all patients attending the clinic.

1021


1022 The anonymity and confidentiality of the patients will be preserved by not revealing
1023 names or any form of identity when collecting data, analysis and reporting the study
1024 findings.

1025

1026 **STUDY TIMELINE**

1027

1028 **Gant Chart**



1029

1030 **BUDGET**

1031 All costs incurred during this study will be self-funded and are estimated at R3000

1032 and divided as follows:

Stationary	R500
Printing of research proposal and related documents	R500
Printing of final research paper	R1 000
Travel expenses	R1000
Total	R3000

1033

1034 Furthermore, The Faculty of Health Sciences at the University of the Witwatersrand
1035 will be approached to assist with publication costs for any journal articles that may
1036 emanate from this research.

1037 REFERENCES

1038

- 1039 1. Abdool-Karim, Q. and S.S. Abdool-Karim, The evolving HIV
1040 epidemic in South Africa. *Int J Epidemiol*, 2002. 31(1): p. 37-40.
- 1041 2. UNAIDS. UNAIDS DATA 2021 South Africa. 2021; Available from:
1042 <https://www.unaids.org/en/regionscountries/countries/southafrica>.
- 1043 3. SA, S. Mortality and causes of death in South Africa, 2017:
1044 Findings from death notification. 2017 2020; Available from:
1045 <https://www.statssa.gov.za/publications/P03093/P030932017.pdf>.
- 1046 4. Abdool Karim, Q. and S.S. Abdool Karim, COVID-19 affects HIV
1047 and tuberculosis care. *Science*, 2020. 369(6502): p. 366-368.
- 1048 5. Vrazo, A.C., et al., Adapting HIV services for pregnant and
1049 breastfeeding women, infants, children, adolescents and families in
1050 resource-constrained settings during the COVID-19 pandemic. *J Int*
1051 *AIDS Soc*, 2020. 23(9): p. e25622.
- 1052 6. Araujo, L.A., et al., The potential impact of the COVID-19
1053 pandemic on child growth and development: a systematic review. *J*
1054 *Pediatr (Rio J)*, 2021. 97(4): p. 369-377.
- 1055 7. Castel, A.D., et al., SARS-CoV-2 and HIV: Epidemiology,
1056 Treatment, and Lessons Learned from HIV. *AIDS Rev*, 2020. 22(3): p.
1057 133-142.
- 1058 8. Coker, M., et al., Things must not fall apart: the ripple effects of the
1059 COVID-19 pandemic on children in sub-Saharan Africa. *Pediatr Res*,
1060 2021. 89(5): p. 1078-1086.
- 1061 9. UNAIDS. Trends of new HIV infections. 2021; Available from:
1062 <https://www.unaids.org/en/resources/fact-sheet>.
- 1063 10. Grimsrud, A. and L. Wilkinson, Acceleration of differentiated
1064 service delivery for HIV treatment in sub-Saharan Africa during COVID-
1065 19. *J Int AIDS Soc*, 2021. 24(6): p. e25704.
- 1066 11. Kanwugu, O.N. and P. Adadi, HIV/SARS-CoV-2 coinfection: A
1067 global perspective. *J Med Virol*, 2021. 93(2): p. 726-732.

12. Dorward, J., et al., The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis. *Lancet HIV*, 2021. 8(3): p. e158-e165.
13. Lesko, C.R. and A.M. Bengtson, HIV and COVID-19: Intersecting Epidemics With Many Unknowns. *Am J Epidemiol*, 2021. 190(1): p. 10-16.
14. M, D., Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a population Cohort Study from the Western Cape Province, South Africa. *Clinical Infectious Diseases*, 2021. 73: p. 2005 - 2015.
15. Abdool Karim, Q. and C. Baxter, COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa. *Current HIV/AIDS Reports*, 2022: p. 1-8.
16. Adugna, A., et al., The Effect of COVID-19 on Routine HIV Care Services from Health Facilities in Northwest Ethiopia. *HIV/AIDS (Auckland, NZ)*, 2021. 13: p. 1159.
17. Armbruster, M., et al., Addressing health inequities exacerbated by COVID-19 among youth with HIV: expanding our toolkit. *Journal of Adolescent Health*, 2020. 67(2): p. 290-295.
18. Harris, P.A., et al., Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*, 2009. 42(2): p. 377-81.

1100 **Appendix 1**
 1101
 1102 **Data Collection Sheet**
 1103

Patient Code:				
Gender:				
Male		Female		
Age at Presentation:				
< 5years		≥ 5 years		
Caregiver:				
Biological parent		Non biological parent		
Date of Diagnosis:				
Date of ART initiation:				
Age at ART initiation:				
	Consultation 1:	Consultation 2:	Consultation 3:	Consultation 4:
Date				
Age				
Duration on ART				
Type of ARVs				
CD4 (Date)				
Viral Load (Date)				
Weight				
Height				
MUAC				
Nutritional Status (WFH/BMI)				
WHO Staging				
Missed Appointment				
Next Follow up date				

1104

1105 **Appendix 2**
 1106
 1107 **Flow Chart**

Name:						Hosp No:
Date						
Age						
Weight (kg)						
Height (cm)						
BMI ≥ 5 years						
MUAC (cm) < 5 years						
Head Circ < 2 years						
BP						
Urine Dipstix						
Co-Trimoxazole						
MVTs						
INH						
TB Meds:						
HAART:						
Other:						
Bloods: CD4 count						
CD4 %						
POC Viral Load						
Viral Load						
WBC						
Hb						
MCV						
PLTs						
RDW						
Neutrophils (Abs)						
Creatinine						
TB investigations						
Cholesterol / Trigs						
Other						
Lab stickers (Barcodes)						
TCB						

1108
 1109
 1110

Appendix 3

Data Sharing Consent

Consent for Data Use Version 5.1 (2018/04/07). Protocol M170778 (amendment approved 2018/07/03 adjusted 2020/07/16)- Please direct any queries to Dr Karl Technau or Sr Lesley Rose at 011 470 9421. This document must be explained to the patient/family member/guardian and child/adolescent and a copy of the signed document is to be given to the patient/family.

CONSENT FORM: USE OF CLINICAL INFORMATION

Dear Guardian, Parent and Patient,

You/your child are currently attending Rahima Moosa Mother and Child Hospital for treatment of problems you/your child are/is currently experiencing. The Hospital not only renders treatment but is also actively involved in conducting research aimed at improving the quality of care we deliver. From time to time such research involves the use of patient records from which information is extracted. The use of such information is subject to:

- 1) Approval from the Committee for Research on Human Subjects (University of the Witwatersrand)
- 2) Anonymity i.e. the identity of the patient from whose file information is extracted is never revealed to anyone but the researcher unless specific consent is obtained to do so.

We are part of an international collaboration called IeDEA that aims to improve our knowledge about HIV/AIDS by sharing information with other sites and doing scientific analysis. We share our routine clinic information (e.g. weight and height measurements, blood test results and treatment details which are all routinely collected) with IeDEA regularly but do not include your name or any identifying details.

Part of the IeDEA work involves specific "LINKAGE" projects where we use identifying details (e.g. names or ID numbers) to match with other databases (e.g. the home affairs data or the cancer register) with the purpose of understanding patient movement between institutions and services. In the process data is transferred with high level security and only by professionals approved by the Ethics committee so that no information is accidentally released. If data is matched with other databases, only the match is reported, not the person who is matched. We will then only use the information to help services improve. Only in rare cases where we see that the match may help us to help you/your child (e.g. we see that a parent of one of the children in our clinic has died) will we act or try help.

As other projects using routinely collected data arise we would like to obtain your consent to use information from your file/your child's file for the purpose of research, subject to the aforementioned conditions. If research arises that needs more detailed information we will approach you for further specific consent first. If you choose not to give consent, this will not compromise your treatment/your child's treatment in any way. If at any time you choose to withdraw consent you are free to do so and will not be prejudiced in any way. For any concerns about the approval processes followed at the University of the Witwatersrand please contact the Human Research Ethics Committee: Ms Zanele Ndlovu (Administrative Officer) 011 717 2700, zanele.ndlovu@wits.ac.za or Mr Rhulani Mkansi (Administrative Officer) 011 717 2656, Rhulani.mkansi@wits.ac.za.

PATIENT NAME:.....

A.

I.....hereby give consent for my/my child's records to be used as per the abovementioned conditions for the purposes of research:

GUARDIAN NAME and RELATION:.....

SIGNATURE:..... **DATE:**.....

CHILD/ADOLESCENT:..... **WITNESS:**.....

B.

I.....do not give consent for my/my child's records to be used:

GUARDIAN NAME and RELATION:.....

SIGNATURE:..... **DATE:**.....

CHILD/ADOLESCENT:..... **WITNESS:**.....

SUBMISSION GUIDELINES TO THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE

An original article provides an overview of innovative research in a particular field within or related to the focus and scope of the journal, presented according to a clear and well-structured format.

Submission status	Open
Word limit	3500-5000 words (excluding the abstract, tables, figures, graphs, and references)
Abstract	maximum: 250 words requires structural headings: Background, Objectives, Method, Results, Conclusion and What this study adds
Main text	requires structural headings, refer to the full structure 'Ethical considerations' is a sub-section in the manuscript and must include: • Name of the ethical review committee • Study approval number • Manner of consent (written, oral) for human participants • Description of measures taken to maintain the confidentiality of data • If the study was not human or animal research or the study was determined to be non-human subjects research or exempt, the authors must provide a statement with those details in this section.
References	60 or less, adhere to the <u>Vancouver referencing style</u>
Tables, figures and graphs	7 or less, adhere to the Illustrations requirements found in the AOSIS House style guide
Formatting requirements	apply the guidelines located on the <u>Formatting requirements page</u> and the <u>AOSIS house style guide</u>
Compulsory supplementary file(s)	he <u>Authorship, disclosure statements, copyright, and license agreement form</u> , <u>Ethical Clearance/Waiver Documentation</u> and any other relevant form applicable to your submission

Ethical clearance/waiver documentation	evidence of ethical clearance for the study, such as the study approval letter or certificate from the Institutional Review Board (IRB), a waiver from the IRB et cetera
---	--

Title: The article's full title should contain a maximum of 95 characters (including spaces).

Abstract: The abstract, written in English, should be no longer than 250 words and must be written in the past tense.

The abstract should give a succinct account of the objectives, methods, results and significance of the matter. The structured abstract for an Original Research article should consist of six paragraphs labelled Background, Objectives, Method, Results, Conclusion and What this study adds.

- ***Background:** Why do we care about the problem?* State the context and purpose of the study. (What practical, scientific or theoretical gap is your research filling?)
- ***Objectives:** What problem are you trying to solve?* What is the scope of your work (e.g. is it a generalised approach or for a specific situation)? Be careful not to use too much jargon.
- ***Method:** How did you go about solving or making progress on the problem?* State how the study was performed and which statistical tests were used. (What did you actually do to get the results?) Clearly express the basic design of the study; name or briefly describe the basic methodology used without going into excessive detail. Be sure to indicate the key techniques used.
- ***Results:** What is the answer?* Present the main findings (that is, as a result of completing the procedure or study, state what you have learnt, invented or created). Identify trends, relative changes or differences on answers to questions.
- ***Conclusion:** What are the implications of your answer?* Briefly summarise any potential implications. (What are the larger implications of your findings, especially for the problem or gap identified in your motivation?)
- ***What this study adds:*** What key insights into the research results and its future function are revealed? How do these insights link to the focus and scope of the journal? It should be a concise statement of the primary contribution of the manuscript; and how it fits within the scope of the journal.

Do not cite references and do not use abbreviations excessively in the abstract.

Introduction: The introduction must contain your argument for the social and scientific value of the study, as well as the aim and objectives:

- **Social value:** The first part of the introduction should make a clear and logical argument for the importance or relevance of the study. Your argument should be supported by the use of evidence from the literature.
- **Scientific value:** The second part of the introduction should make a clear and logical argument for the originality of the study. This should include a summary of what is already known about the research question or specific topic and should clarify the knowledge gap that this study will address. Your argument should be supported by the use of evidence from the literature.
- **Conceptual framework:** In some research articles it will also be important to describe the underlying theoretical basis for the research and how these theories are linked together in a conceptual framework. The theoretical evidence used to construct the conceptual framework should be referenced from the literature.
- **Aim and objectives:** The introduction should conclude with a clear summary of the aim and objectives of this study.

Research methods and design: This must address the following:

- **Study design:** An outline of the type of study design.

- 1232 • Setting: A description of the setting for the study; for example, the type of community
1233 from which the participants came or the nature of the health system and services in which
1234 the study is conducted.
- 1235 • Study population and sampling strategy: Describe the study population and any inclusion
1236 or exclusion criteria. Describe the intended sample size and your sample size calculation or
1237 justification. Describe the sampling strategy used. Describe in practical terms how this was
1238 implemented.
- 1239 • Intervention (if appropriate): If there were intervention and comparison groups, describe
1240 the intervention in detail and what happened to the comparison groups.
- 1241 • Data collection: Define the data collection tools that were used and their validity. Describe
1242 in practical terms how data were collected and any key issues involved, e.g. language
1243 barriers.
- 1244 • Data analysis: Describe how data were captured, checked and cleaned. Describe the
1245 analysis process, for example, the statistical tests used or steps followed in qualitative
1246 data analysis.
- 1247 • Ethical considerations: Approval must have been obtained for all studies from the author's
1248 institution or other relevant ethics committee and the institution's name and permit
1249 numbers should be stated here.
- 1250 **Results:** Present the results of your study in a logical sequence that addresses the aim and
1251 objectives of your study. Use tables and figures as required to present your findings. Use
1252 quotations as required to establish your interpretation of qualitative data. All units should conform
1253 to the **SI convention** and be abbreviated accordingly. Metric units and their international symbols
1254 are used throughout, as is the decimal point (not the decimal comma).
1255
- 1256 **Discussion:** The discussion section should address the following four elements:
- 1257 • Key findings: Summarise the key findings without reiterating details of the results.
- 1258 • Discussion of key findings: Explain how the key findings relate to previous research or to
1259 existing knowledge, practice or policy.
- 1260 • Strengths and limitations: Describe the strengths and limitations of your methods and
1261 what the reader should take into account when interpreting your results.
- 1262 • Implications or recommendations: State the implications of your study or
1263 recommendations for future research (questions that remain unanswered), policy or
1264 practice. Make sure that the recommendations flow directly from your findings.
- 1265 **Conclusion:** Provide a brief conclusion that summarises the results and their meaning or
1266 significance in relation to each objective of the study.
1267
- 1268 **Acknowledgements:** Those who contributed to the work but do not meet our authorship criteria
1269 should be listed in the Acknowledgments with a description of the contribution. Authors are
1270 responsible for ensuring that anyone named in the Acknowledgments agrees to be named. Refer to
1271 the acknowledgement structure guide on our *Formatting Requirements* page.
1272
- 1273 Also provide the following, each under their own heading:
- 1274 • Competing interests: This section should list specific competing interests associated with
1275 any of the authors. If authors declare that no competing interests exist, the article will
1276 include a statement to this effect: *The authors declare that they have no financial or
1277 personal relationship(s) that may have inappropriately influenced them in writing this
1278 article.* Read our **policy on competing interests**.
- 1279 • Author contributions: All authors must meet the criteria for authorship as outlined in
1280 the **authorship** policy and **author contribution** statement policies.
- 1281 • Funding: Provide information on funding if relevant
- 1282 • Data availability: All research articles are encouraged to have a data availability statement.

- Disclaimer: A statement that the views expressed in the submitted article are his or her own and not an official position of the institution or funder.

References: Authors should provide direct references to original research sources whenever possible. References should not be used by authors, editors, or peer reviewers to promote self-interests. Refer to the journal referencing style downloadable on our *Formatting Requirements* page.

Cover Letter

The authorship, disclosure statements, copyright, and license agreement form is our compulsory cover letter which needs to form part of your submission. Kindly download and complete, in English, the provided **form**.

Anyone that has made a significant contribution to the research and the paper must be listed as an author in your cover letter. Contributions that fall short of meeting the criteria as stipulated in our policy should rather be mentioned in the 'Acknowledgements' section of the manuscript.

Read our **authorship** guidelines and **author contribution** statement policies.

1305 Style and format

1306
1307

File format

- 1308
- Manuscript files can be in the following formats: DOC, DOCX, or RTF. Microsoft Word documents should not be locked or protected.
- 1309
- 1310
- LaTeX documents (.tex) should be converted into Microsoft Word (.doc) before submission online.
- 1311
- 1312
- Rich Text Format (RTF): Users of other word processing packages should save or convert their files to RTF before uploading. Many free tools are available that will make this process easier.
- 1313
- 1314

Length

1315 Manuscripts should adhere to the author guidelines of the journal. There are restrictions on word count, number of figures, or amount of supporting information.

1316

1317

1318

Font

1319 Use a standard font size and any standard font family.

1320

1321

Special characters

1322 Do not use the font named 'Symbol'. To add symbols to the manuscript, use the Insert → Symbol function in your word processor or paste in the appropriate Unicode character. Refer to our AOSIS house style guide on mathematical and Unicode font guidelines.

1323

1324

1325

1326

Headings

1327 Ensure that formatting for headings is consistent in the manuscript. Limit manuscript sections and sub-sections to four heading levels. To avoid confusion during the review and production process, ensure that the different heading levels used in your work are visually distinct from one another. The simplest way to achieve this is to use different font sizes and/or a combination of bold/italics for different heading levels.

1328

1329

1330

1331

1332

1333

Keywords

1334 Identify eight keywords that represent the content of your manuscript and are specific to your field or sub-field. Test your keywords: when you enter your keywords into the various journal and academic databases like Google Scholar, do the results include papers similar to your topic? If not, revise the terms until they do.

1335

1336

1337

1338

1339

Layout and spacing

1340 Manuscript text should have a 1.5 line spacing.

1341

1342

Page and line numbers

1343 Include page numbers and line numbers in the manuscript file. Use continuous line numbers (do not restart the numbering on each page).

1344

1345

1346

Footnotes

1347 Footnotes are not ideal. If your manuscript contains footnotes, move the information into the main text or the reference list, depending on the content.

1348

1349

1350

Language

1351 Manuscripts must be written in British English, according to the Oxford English Dictionary (avoid Americanisms [e.g. use 's' and not 'z' spellings], and set your version of Microsoft Word default language to UK English). Refer to the AOSIS house style guide for more information.

1352

1353

1354

1355

Abbreviations

1356 Define abbreviations upon first appearance in the text. Do not use non-standard abbreviations unless they appear at least three times in the text. Keep abbreviations to a minimum.

1357

1358

1359

Illustrations

1360 Illustrations fall into two categories:

1361

- 1362
- Figures: Photographs, drawings, diagrams, graphs, flowcharts, maps, etc.
- 1363
- Tables and/or Boxes: Text and/or numbers arranged in orderly columns and rows.

1364 Every time a Figure, Table and/or Box is presented in your manuscript, it should be referred to
1365 three times:

- 1366 • In a legend, which includes a number, a title, and its source. The legend is placed below a
1367 Figure and above a Table and/or Box. The source section should consist of the in-text
1368 citation, creator or owner and its year of creation, and any other attribution required as
1369 stipulated by the permission received (person and place) to reproduce.
- 1370 • In the body of your written manuscript. You should include an in-text citation and a
1371 sentence or two about the image explaining what it illustrates and why it is there.
- 1372 • As a reference entry within your reference list.

1373 **AOSIS house style**
1374 The manuscript must adhere to the **AOSIS house style guide**.

1375 **References**

1376 **Referencing style guide**
1377 The manuscript must adhere to the **Vancouver referencing style**.

1378 **Permission to use copyright material**

1379 The following information will assist you in understanding your responsibilities and in requesting
1380 permission to reproduce copyrighted material in your work. All permissions granted must be
1381 submitted to the journal together with your manuscript, and you must ensure that a clearly written
1382 source accompanies the work.

1383 **Your responsibilities**
1384 As the author, you are responsible for obtaining permission and paying any fees to use the third-
1385 party copyrighted material that your manuscript contains.

1386 **Material that will need clearance**
1387 Content not in the public domain or freely available to use under a license such as a creative
1388 commons license will require clearance. It includes the use of photographs, figures, maps, tables,
1389 cartoons, advertisements, epigraphs and quotations that are over the limits referred to under
1390 'Modification/adaptation of figures and tables'.

1391 **Web material**
1392 Image or text material on the Web may not be the intellectual property of the site hosting it. You
1393 must always identify the original copyright source and obtain explicit permission. Take particular
1394 care with photographs obtained from websites, blogs, Google image searches, YouTube,
1395 Wikimedia, etc.

1396 **Material previously published by you or your colleague**
1397 Check the contract with the other publisher to see whether, and under what conditions, the
1398 material can be reused in this AOSIS publication. If in any doubt, permission must be obtained.

1399 **Images of, or information about, identifiable individuals**
1400 It is your responsibility to obtain consent from patients and other individuals for the use of
1401 information, images, audio files, and video clips from which they may be identified. Bear in mind
1402 the following points:

- 1403 • Masking a person's eyes is not an adequate or acceptable means of rendering an image
1404 anonymous.
- 1405 • People may still be recognizable to individuals or their families, even if head/shoulders are
1406 not included.
- 1407 • People may recognize themselves from clinical descriptions or case reports.

1408 **Modification/adaptation of figures and tables**
1409 Use the original figure as first published where appropriate. However:

- 1410 • No clearance is required if you create figures or tables using factual data from copyrighted
1411 material.

- No clearance is required if, after you have created a single figure or table using data from two or more figures or tables, no single source comprises more than 75% of the new figure or table.
- No clearance is required if, after you have created a new figure or table by adding your own data to an existing figure or table, your data comprises more than 25% of the new figure or table.
- Clearance is required if you create a figure or table using parts from two or more third-party sources, and each part contains more than 75% of the content of the original figure/table part.

Quotations

For prose, permission is required for single quotations of over 400 words or multiple quotations from the same source that cumulatively total more than 800 words. But note that, even if below these limits, permissions must be cleared for quotations that represent the ‘heart of the work’ or a substantial portion of the overall original source material.

Clear before you submit your final manuscript

Permissions must be cleared before the final version of your manuscript is submitted for publication. If permission cannot be obtained, you should find an alternative or remove the material. Provide electronic copies of all consent forms obtained when you submit your final manuscript, numbered and named accordingly.

Ethical considerations

This section should include the statements of compliance with standards of research involving either animal or human involvement. If your study involves human subjects and/or animals, and if your manuscript includes case reports/case series, you need to provide the following:

- Authors must provide the name of the ethical approval committee/Institutional Review Board they have obtained consent from and approval number/ID.
- Authors should specifically mention if a waiver was obtained for the study and the reason for the waiver. They should confirm that the study was conducted in accordance with Helsinki Declaration as revised in 2013.
- Authors must state that written informed consent was obtained from the participants of the study (and the relevant document(s) must be provided when requested by the journal). If verbal informed consent was obtained, the reason(s) for the absence of written consent must be provided.
- For case reports/case series involving minor subjects/children/infants, authors should confirm that the statements of written informed consent from legally authorized representatives/parents/guardians are available; if verbal informed consent was obtained, reasons for this must be mentioned.
- Since patients have a right to privacy, identifying information (including patients’ images, names, initials, or hospital numbers) should not be included in recordings, written descriptions, or photographs unless the information is essential for scientific purposes. In any case, written informed consent from the patient must be obtained for publication of these graphics in print and electronic form. If such consent has not been obtained, personal details of patients in any part of the paper and in any supplementary materials (including illustrations) must be removed before submission.

Subject	Scenario	Suggested statement of compliance
Animals: Include the statement of compliance with standards of research involving animals.	If your work includes animals, it is necessary to have a statement of compliance with research standards involving animals.	All procedures performed in studies involving animals followed all international, national, and/or institutional guidelines for the care and use of animals.

	If you publish an article and there are reasons to <u>believe</u> that you could have used animals but did not.	This article does not contain any studies involving animals performed by any of the authors.
Humans: Include the statement of compliance with standards of research involving humans.	If your work does not include humans as subjects, you may finish the ethical statement to include.	This article does not contain any studies involving human participants performed by any of the authors.
	If your work involves humans as a subject, you had to receive ethics approval.	An application for full ethical approval was made to the [committee/Institutional Review Board] and ethics consent was received on [date]. The ethics approval number is [full ethics approval number].
	If your work involves humans as a subject, but you received an ethics waiver.	An application for full ethical approval was made to the [committee/Institutional Review Board] and ethics consent was received on [date]. The ethics waiver number is [full number]. The [committee/Institutional Review Board] issued an ethics waiver for the study because [reason for the ethics waiver].
	Additional statements: If your work involves humans, it is necessary to <u>include one of the above and the following two additional statements</u> .	All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. ^a Informed Consent: [Written/Verbal] informed consent was obtained from all individual participants involved in the study. [If verbal informed consent was obtained, the reason(s) for the absence of written consent must be provided.]

^a, Do keep in mind: The necessary and sufficient condition is to conduct research in accordance with the **1964 Helsinki Declaration**. If your institution has no department that deals with ethics, then you should not mention institutional standards. If your country has no committee that deals with ethics, then you should not mention national standards.

Acknowledgements structure

Acknowledgements

The acknowledgement section follows the conclusions section and addresses formal, required statements of gratitude and required disclosures. It includes listing those who contributed to the work but did not meet authorship criteria, with the corresponding description of the contribution. Acknowledge anyone who provided intellectual assistance, technical help (including with writing and editing), or special equipment and/or materials. Authors are responsible for ensuring that anyone named in the Acknowledgements agrees to be named.

Also provide the following, each under their own subheading:

- Competing interests
- Author contributions
- Funding information
- Data availability statement
- Disclaimer

Competing interests

This section should list specific competing interests associated with any of the authors. If authors declare that no competing interests exist, the article will include a statement to this effect. Read our [policy on competing interests](#).

The following are examples of competing interest statements. If you use one of the examples, you should modify it to fit your specific relationship.

Scenario	Suggested competing interest statements
Example 1	The author(s) declare that they have no financial or personal relationship(s) that may have inappropriately influenced them in writing this article.
Example 2	The author reported that they [have a financial and/or business interests in] [are a consultant to] [received funding from] a company that may be affected by the research reported in the enclosed publication. They have disclosed those interests fully and have in place an approved plan for managing any potential conflicts arising from [that involvement].
Example 3	A.B. developed the theoretical formalism, performed the analytic calculations and performed the numerical simulations. Both A.B and B.C. contributed to the final version of the manuscript. B.C. supervised the project.
Example 4	A.B., B.C., C.D., D.E., E.F., F.G., and G.H. conceived and planned the experiments. A.B., B.C., C.D. and D.E. carried out the experiments. A.B., F.G. and E.F. planned and carried out the simulations. J.K., K.L., A.B., B.C., D.E., C.D., F.J., and F.G. contributed to sample preparation. A.B., B.C., C.D., D.E., F.J., E.F., F.G. and G.H. contributed to the interpretation of the results. A.B. took the lead in writing the manuscript. All authors provided critical feedback and helped shape the research, analysis and manuscript.
Example 5	A.B. and B.C. designed the model and the computational framework and analysed the data. A.B. and C.D. carried out the implementation. A.B. performed the calculations. A.B. and B.C. wrote the manuscript with input from all authors. D.E. and E.F. conceived the study and were in charge of overall direction and planning.
Example 6	A.B. designed and performed the experiments, derived the models and analysed the data. B.C. assisted with XYZ measurements and C.D. helped carry out the XYZ simulations. A.B. and D.E. wrote the manuscript in consultation with C.D., B.C. and E.F..

Example 7	A.B. devised the project, the main conceptual ideas and proof outline. B.C. worked out almost all of the technical details, and performed the numerical calculations for the suggested experiment. C.D. worked out the bound for quantum mechanics, with help from D.E.. E.F. verified the numerical results of the XYZ by an independent implementation. F.G. and G.H. proposed the XYZ experiment in discussions with A.B.. B.C., C.D., G.H. and A.B. wrote the manuscript.
Example 8	A.B., B.C. and C.D. designed the study. A.B., D.E. and E.F. performed the XYZ experiments. F.G. and G.H. performed XYZ simulations. I.H. and M.C. expressed and purified all proteins. A.B., H.J., B.C. and C.D. analysed the data. A.B., B.C. and C.D. wrote the paper with input from all authors.
Example 9	A.B. and B.C. designed and directed the project; C.D., D.E., A.B. and B.C. performed the experiments; C.D. and B.C. analysed spectra; A.B. and E.F. made the simulations; B.C. developed the theoretical framework; C.D., A.B. and B.C. wrote the article.
Example 10	The author of this publication receives research funding from [Entity], which is developing products related to the research described in this publication. In addition, the author serves as a consultant to [Entity] and receives compensation for these services. The terms of this arrangement have been reviewed and approved by the [University name; Institution name] in accordance with its policy on objectivity in research.
Example 11	The author of this publication receives research support from [name of research sponsor] with an equipment loan from [Entity]. The author also [has an equity interest in, serves as a consultant to, serves on an advisory board or board of directors for] [Entity]. The terms of this arrangement have been reviewed and approved by the [University name; Institution name] in accordance with its policy on objectivity in research.

Author contributions

All authors must meet the criteria for authorship as outlined in the [authorship](#) policy and [author contribution](#) statement policies.

The following are examples of an author contribution statement. If you use one of the examples, you should modify it to fit your specific relationship.

Scenario	Suggested author contribution statements
Example 1	A.B. and B.C. conceived of the presented idea. A.B. developed the theory and performed the computations. C.D. and D.E. verified the analytical methods. B.C. encouraged A.B. to investigate [a specific aspect] and supervised the findings of this work. All authors discussed the results and contributed to the final manuscript.
Example 2	A.B. and B.C. carried out the experiment. A.B. wrote the manuscript with support from C.D.. D.E. and E.F. fabricated the XYZ sample. F.G. and G.H. helped supervise the project. G.H. and H.I. conceived the original idea. H.I. supervised the project.
Example 3	A.B. developed the theoretical formalism, performed the analytic calculations and performed the numerical simulations. Both A.B and B.C. authors contributed to the final version of the manuscript. B.C. supervised the project.
Example 4	A.B., B.C., C.D., D.E., E.F., F.G., and G.H. conceived and planned the experiments. A.B., B.C., C.D. and D.E. carried out the experiments. A.B., F.G. and E.F. planned and carried out the simulations. J.K., K.L., A.B., B.C., D.E., C.D., F.J., and F.G. contributed to sample preparation. A.B., B.C., C.D., D.E., F.J, E.F., F.G. and G.H. contributed to the interpretation of the results. A.B. took

	the lead in writing the manuscript. All authors provided critical feedback and helped shape the research, analysis and manuscript.
Example 5	A.B. and B.C. designed the model and the computational framework and analysed the data. A.B. and C.D. carried out the implementation. A.B. performed the calculations. A.B. and B.C. wrote the manuscript with input from all authors. D.E. and E.F. conceived the study and were in charge of overall direction and planning.
Example 6	A.B. designed and performed the experiments, derived the models and analysed the data. B.C. assisted with XYZ measurements and C.D. helped carry out the XYZ simulations. A.B. and D.E. wrote the manuscript in consultation with C.D., B.C. and E.F..
Example 7	A.B. devised the project, the main conceptual ideas and proof outline. B.C. worked out almost all of the technical details, and performed the numerical calculations for the suggested experiment. C.D. worked out the bound for quantum mechanics, with help from D.E.. E.F. verified the numerical results of the xyz by an independent implementation. F.G. and G.H. proposed the xyz experiment in discussions with A.B.. B.C., C.D., G.H. and A.B. wrote the manuscript.
Example 8	A.B., B.C. and C.D. designed the study. A.B., D.E. and E.F. performed the xyz experiments. F.G. and G.H. performed XYZ simulations. I.H. and M.C. expressed and purified all proteins. A.B., H.J., B.C. and C.D. analysed the data. A.B., B.C. and C.D. wrote the paper with input from all authors.
Example 9	A.B. and B.C. designed and directed the project; C.D., D.E., A.B. and B.C. performed the experiments; C.D. and B.C. analysed spectra; A.B. and E.F. made the simulations; B.C. developed the theoretical framework; C.D., A.B. and B.C. wrote the article.
Example 10	A.B., B.C. and C.D. performed the measurements, D.E. and E.F. were involved in planning and supervised the work, A.B. and B.C. processed the experimental data, performed the analysis, drafted the manuscript and designed the figures. F.G., and G.H. performed the xyz calculations. H.I., and I.J. manufactured the samples and characterized them with xyz spectroscopy, J.K. performed the xyz characterization. K.L. aided in interpreting the results and worked on the manuscript. All authors discussed the results and commented on the manuscript.
Example 11	A.B., B.C., C.D. and D.E. contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript.

Funding information

All research articles should have a funding acknowledgement statement included in the manuscript in the form of a sentence under a separate heading entitled 'Funding information'. The funding agency should be written out in full, followed by the grant number in square brackets.

The following are examples of a funding statement. If you use one of the examples, you should modify it to fit your specific relationship.

Scenario	Suggested funding statements
Example 1	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Medical Research Council [grant number xxx].
Example 2	This work was supported by the Trust [grant numbers xxxx, yyyy]; the Natural Environment Research Council [grant number zzzz]; and the Economic and Social Research Council [grant number aaaa].

Example 3	The author(s) received no financial support for the research, authorship, and/or publication of this article.
-----------	---

Data availability statement

All research articles should have a data availability statement included in the manuscript in the form of a sentence under a separate heading entitled 'Data availability statement'.

The following are examples of a data availability statement. If you use one of the examples, you should modify it to fit your specific relationship.

Availability of data	Suggested data availability statements
Data openly available in a public repository that issues datasets with DOIs	The data that support the findings of this study are openly available in [repository name e.g 'figshare'] at http://doi.org/[doi] , reference number [reference number].
Data openly available in a public repository that does not issue DOIs	The data that support the findings of this study are openly available in [repository name] at [URL], reference number [reference number].
Data derived from public domain resources	The data that support the findings of this study are available in [repository name] at [URL/DOI], reference number [reference number]. These data were derived from the following resources available in the public domain: [list resources and URLs]
Data available within the article or its supplementary materials	The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.
Data generated at a central, large-scale facility, available upon request	Raw data were generated at [facility name]. Derived data supporting the findings of this study are available from the corresponding author [initials] on request.
Embargo on data due to commercial restrictions	The data that support the findings will be available in [repository name] at [URL / DOI link] following a [6 month] embargo from the date of publication to allow for the commercialisation of research findings.
Data available on request due to privacy/ethical restrictions	The data that support the findings of this study are available on request from the corresponding author, [initials]. The data are not publicly available due to [restrictions, e.g. their containing information that could compromise the privacy of research participants].
Data subject to third party restrictions	The data that support the findings of this study are available [from] [third party]. Restrictions apply to the availability of these data, which were used under licence for this study. Data are available [from the authors / at URL] with the permission of [third party].

Data available on request from the authors	The data that support the findings of this study are not openly available due to [reasons of sensitivity, e.g. human data] and are available from the corresponding author, [author initials], upon reasonable request [include information on the data's location, e.g. in a controlled access repository where relevant].
Data sharing not applicable – no new data generated	Data sharing is not applicable to this article, as no new data were created or analysed in this study.

Disclaimer

A statement that the views expressed in the submitted article are his or her own and not an official position of the institution or funder.